Peptimmune, Inc. Garners $8,200,000 Series D Financing Round

  • Feed Type
  • Date
  • Company Name
    Peptimmune, Inc.
  • Mailing Address
    64 Sidney Street Cambridge, MA 02139
  • Company Description
    Peptimmune is a clinical stage biotechnology company that is utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds of the $8.2 million second tranche are expected to be used mainly to advance clinical development of Peptimmune’s multiple sclerosis treatment, PI-2301. More than 400,000 Americans have multiple sclerosis (MS), and worldwide MS may affect over 2.5 million individuals, according to the company.
  • M&A Terms
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    MPM Capital
  • Venture Investor
    Hunt Ventures
  • Venture Investor
    Silicon Valley Bank

Trending on Xconomy